Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLPDEN-02 Dengue Vaccine in Healthy Adults
NCT07831473Phase 1Not yet recruiting
- Sponsor
- VLP Therapeutics
- Start
- Jan 2027
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VLPDEN-02 + ALFQ in dengue fever (3 cohorts), sponsored by VLP Therapeutics. Primary endpoint: Safety and Reactogenicity Assessment at 7 days. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
VLPDEN-02 + ALFQ
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT07831473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831473.